Spectral AI Announces Total U.S. and International Patent Portfolio Now Stands at 26 Granted Patents and 38 Pending Applications in Support of its AI-Driven DeepView System
July 24 2024 - 8:00AM
Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the
“Company”), an artificial intelligence (AI) company
focused on medical diagnostics for faster and more accurate
treatment decisions in wound care, today announced a 30% increase
in its patent portfolio that strengthens and protects its
proprietary, AI-driven DeepView System wound assessment platform.
Total patents granted to the Company increased
to 26 through July 8, 2024 from 20 at December 31, 2023, consisting
of 12 U.S. and 14 international patents. These patents cover
various aspects of the Company’s DeepView System platform,
including, but not limited to, tissue classification based on
multi-spectral imaging, machine learning and healthcare metrics,
wound assessments based on multi-spectral imaging, optical
biomarkers, machine learning and high precision imaging with
multiplexed illumination.
The Company continues to protect its data and
processes with an additional 38 pending patent applications
worldwide, consisting of seven pending U.S. patents and 31 pending
international patents. The patents encompass nine distinct patent
families.
“These newly granted patents highlight the novel
nature of our DeepView System platform and its ability to deliver
an immediate, objective, and grounded assessment of a wound’s
healing potential,” said Peter M. Carslon, Chief Executive Officer.
“The DeepView System platform reflects years of significant
investment in product development and our team is continuing to
enhance the underlying technology. Together with our trademarks and
trade secrets, these intellectual property assets are keys to our
success and will serve as a foundation for our planned product
commercialization initiatives set to commence in late 2024 and
continuing through 2026.”
“We remain diligent in protecting and enhancing
our proprietary technologies,” said Erich Spangenberg, Spectral AI
board member, a globally recognized IP expert, and the Company’s
largest shareholder. “I am actively engaged in supporting
management as it builds and maintains a world-class moat around
these critical assets.”
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive
AI company focused on medical diagnostics for faster and more
accurate treatment decisions in wound care, with initial
applications involving patients with burns and diabetic foot
ulcers. The Company is working to revolutionize the management of
wound care by “Seeing the Unknown®” with its DeepView System. The
DeepView System is a predictive device that offers clinicians an
objective and immediate assessment of a wound’s healing potential
prior to treatment or other medical intervention. With
algorithm-driven results and a goal to change the current standard
of care, the DeepView System is expected to provide faster and more
accurate treatment insight towards value care by improving patient
outcomes and reducing healthcare costs. For more information about
the DeepView System, visit www.spectral-ai.com.
Forward Looking
Statements Certain statements made in this release
are “forward looking statements” within the meaning of the “safe
harbor” provisions of the United States Private Securities
Litigation Reform Act of 1995, including statements regarding the
Company’s strategy, plans, objectives, initiatives and financial
outlook. When used in this press release, the words “estimates,”
“projected,” “expects,” “anticipates,” “forecasts,” “plans,”
“intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,”
“propose” and variations of these words or similar expressions (or
the negative versions of such words or expressions) are intended to
identify forward-looking statements.
These forward-looking statements are not
guarantees of future performance, conditions or results, and
involve a number of known and unknown risks, uncertainties,
assumptions and other important factors, many of which are outside
Company’s control, that could cause actual results or outcomes to
differ materially from those discussed in the forward-looking
statements. As such, readers are cautioned not to place undue
reliance on any forward-looking statements.
Investors should carefully consider the
foregoing factors and the other risks and uncertainties described
in the “Risk Factors” sections of the Company’s filings with the
SEC, including the Registration Statement and the other documents
filed by the Company. These filings identify and address other
important risks and uncertainties that could cause actual events
and results to differ materially from those contained in the
forward-looking statements.
Investors: The Equity
Group Devin Sullivan Managing
Director dsullivan@equityny.com
Conor Rodriguez Analyst crodriguez@equityny.com
Spectral AI (NASDAQ:MDAI)
Historical Stock Chart
From Sep 2024 to Oct 2024
Spectral AI (NASDAQ:MDAI)
Historical Stock Chart
From Oct 2023 to Oct 2024